The goal of Scott Armstrong’s research program is to define genetic and epigenetic programs that control the extensive self-renewal properties associated with leukemia and other cancers. This knowledge is then used to develop rational approaches for potential new therapies. Experiments incorporate the use of sophisticated mouse models of leukemia and the characterization of human leukemia cells.
Scott A. Armstrong, MD, PhD
Director, Center for Epigenetics Research; Director, Leukemia Center
Research FocusPhysician-scientist Scott Armstrong focuses on defining genetic and epigenetic programs that control the extensive self-renewal properties associated with leukemia and other cancers.
- MD, PhD, University of Texas Southwestern Medical Center Dallas
- Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA. Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9. Nature. 2006 Aug 17;442(7104):818-22. Epub 2006 Jul 16.
- Krivtsov AV, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, Kutok JL, Kung AL, Armstrong SA. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008 Nov 4;14(5):355-68. doi: 10.1016/j.ccr.2008.10.001.
- Claire W. and Richard P. Morse Research Award, Dana-Farber Cancer Institute (2002)
- Wilson S. Stone Award, M. D. Anderson Cancer Center (2006)
- McCulloch and Till Award, International Society of Experimental Hematology (2009)
- Member, American Society for Clinical Investigation (2010)
- Paul Marks Prize for Cancer Research, Memorial Sloan Kettering Cancer Center (2011)
- E. Mead Johnson Award for Research in Pediatrics (2012)
- Dameshek Prize , American Society of Hematology (2104)
- Frank A. Oski Award, American Society of Pediatric Hematology/ Oncology
- Member, Association of American Physicians (2014)